Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor Trial. Approximately $30 Million in Cash and Short-Term investments
-
Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares
-
GENENTA AND ANEMOCYTE ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE OFF-THE-SHELF LVV PLASMID DNA PRODUCTION
-
Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals
-
Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell based therapies
-
CEO Genenta Science (Nasdaq: GNTA) will present at “Montalcini Global Biotech Tour Doha April 17, 2025
-
Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates
-
Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing
-
Genenta’s CEO to present at the U.S. Senate, Washington D.C.at the meeting “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatl
-
Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer